Proteasis Evaluation in COPD

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01713335

Acronym

Pro-BPCO

Enrollment

134

Registered

2012-10-24

Start date

2012-10-18

Completion date

2017-04-30

Last updated

2021-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients. Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be included: Healthy smoker subjects, stable COPD patients and COPD patients with acute exacerbation. Kallicrein levels in sputum will be compared in these groups.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

50 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

for healthy subjects: * Smoker with tobacco consumption of 20 pack/year * Normal lung function tests

Exclusion criteria

for healthy subjects: * diagnosis of lung disease during the study * Asthma * Lung cancer * Pregnant and lactating women Inclusion Criteria for stable COPD: * Smoker with tobacco consumption of 20 pack/year * FEV1/FVC\<70% on lung function tests * no hospitalisation for exacerbation during 3 months before inclusion

Design outcomes

Primary

Measure	Time frame
Kallikrein level in sputum by ELISA	One sample at inclusion

Secondary

Measure	Time frame	Description
Comparison between kallikrein level and clinical or functionnal parameters	All data will be identified at inclusion	Correlation between kallikrein and FEV1 Correlation between kallikrein and dyspnea score

Countries

France

Outcome results